Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nocturnal asthma.

E Rand Sutherland1

  • 1National Jewish Medical and Research Center and the University of Colorado Health Sciences Center, Denver, CO 80206, USA. sutherlande@njc.org

The Journal of Allergy and Clinical Immunology
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

Journal of the American Academy of Dermatology·2016
Same author

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Lancet (London, England)·2016
Same author

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

JAMA·2016
Same author

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

Lancet (London, England)·2015
Same author

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.

Pulmonary pharmacology & therapeutics·2015
Same author

Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2015
Same journal

Corrigendum.

The Journal of allergy and clinical immunology·2026
Same journal

Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.

The Journal of allergy and clinical immunology·2026
Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026
Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026
Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026
See all related articles

Nocturnal asthma symptoms are common, affecting many patients nightly. Understanding circadian variations and potential hormonal influences is key to optimizing treatment timing for better symptom control.

Area of Science:

  • Pulmonary Medicine
  • Sleep Medicine
  • Chronobiology

Background:

  • Nocturnal asthma symptoms, including nighttime awakenings due to cough and dyspnea, are prevalent in asthma patients.
  • Approximately 40% of asthmatic individuals experience nightly symptoms, significantly impacting quality of life.

Purpose of the Study:

  • To review the pathophysiology of nocturnal asthma, focusing on circadian variations in airway inflammation and lung function.
  • To explore potential contributing factors such as receptor alterations and melatonin's role.
  • To discuss optimized treatment strategies for managing nocturnal asthma symptoms.

Main Methods:

  • Literature review of studies investigating nocturnal asthma symptoms and lung function.
  • Analysis of research on circadian rhythms in asthma.

Related Experiment Videos

  • Examination of studies on hormonal influences (beta2-adrenergic receptors, glucocorticoid receptors, HPA axis, melatonin) on nocturnal asthma.

    • Main Results:

    • Nocturnal asthma is characterized by circadian variations in airway inflammation, airflow limitation, and airway hyperresponsiveness.
    • Alterations in specific receptors and hypothalamic-pituitary-adrenal axis function may contribute to the nocturnal phenotype.
    • Melatonin, a regulator of circadian rhythms, is implicated in the pathophysiology of nocturnal asthma.

    Conclusions:

    • Nocturnal asthma is a distinct clinical manifestation requiring specific management considerations.
    • Understanding circadian variations and hormonal factors is crucial for effective treatment.
    • Timing medication doses to coincide with nocturnal symptom exacerbations can improve therapeutic outcomes.